McKibbin, Martin <br/><br/>
CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.  [electronic resource] 

 -  The British journal of ophthalmology  Feb 2012 
 - 208-12 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-2079 
<br/><br/><label>Standard No.: </label>10.1136/bjo.2010.193680  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Complement Factor H--genetics<br/>Female<br/>Fluorescein Angiography<br/>Genotype<br/>High-Temperature Requirement A Serine Peptidase 1<br/>Humans<br/>Indocyanine Green<br/>Intravitreal Injections<br/>Male<br/>Pilot Projects<br/>Polymerase Chain Reaction<br/>Polymorphism, Single Nucleotide<br/>Promoter Regions, Genetic--genetics<br/>Ranibizumab<br/>Serine Endopeptidases--genetics<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--genetics<br/>Visual Acuity--physiology<br/>Wet Macular Degeneration--drug therapy